Brief: Clover’S Covid-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron As A Homologous Booster
27/06/2022 11:44
June 27 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* CLOVER’S COVID-19 VACCINE CANDIDATE DEMONSTRATES STRONG
CROSS-NEUTRALIZATION AGAINST OMICRON AS A HOMOLOGOUS BOOSTER
* CLOVER BIOPHARMACEUTICALS - SCB-2019 AS A THIRD DOSE
EXHIBITED
19-FOLD BOOST IN NEUTRALIZING ANTIBODIES AGAINST OMICRON BA.2
VARIANT
Source text for Eikon: ID:nGNXrBnkF
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune